Treatment sequence network meta-analysis in Crohn’s disease: a methodological case study

References

• Floyd DN, Langham S, Severac HC, et al. The economic and quality-of-life burden of Crohn’s disease in Europe and the United States, 2000 to 2013: a systematic review. Dig Dis Sci. 2015;60:299–312.
   PubMed Web of Science ®Google Scholar
• van der Have M, van der Aalst KS, Kaptein AA, et al. Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8:93–106.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223.
   PubMed Web of Science ®Google Scholar
• World Gastroenterology Organisation. Inflammatory Bowel Disease [Internet]. 2015 [cited 2018 Apr 5]. Available from: http://www.worldgastroenterology.org/UserFiles/file/guidelines/inflammatory-bowel-disease-english-2015-update.pdf
   Google Scholar
• A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) [Internet]. 2015 [cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01369329
   Google Scholar
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease (UNITI-2) [Internet]. 2015 [cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01369342
   Google Scholar
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease (IM-UNITI) [Internet]. 2016 [cited 2018 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01369355
   Google Scholar
• Bonovas S, Moja L, Danese S. In the presence of conceptual heterogeneity, results of network meta-analysis comparing therapies in Crohn’s disease need to be interpreted with caution. Gastroenterology. 2015;148:1483–1484.
   PubMed Web of Science ®Google Scholar
• Hazlewood G, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148:344–354.
   PubMed Web of Science ®Google Scholar
• Su C, Lichtenstein G, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease. Gastroenterology. 2004;126:1257–1269.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Toor K, et al. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol. 2015;9:693–700.
   PubMed Web of Science ®Google Scholar
• Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Br Med J. 2005;331:897.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton A, Ades A, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607–617.
   PubMed Web of Science ®Google Scholar
• NICE. Single technology appraisal: user guide for company evidence submission template. 2015 [cited 2018 Apr 5]. Available from: https://www.nice.org.uk/process/pmg24/chapter/instructions-for-companies.
   Google Scholar
• Beyer-Westendorf J, Büller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost. 2011;9:2153–2158.
   PubMed Web of Science ®Google Scholar
• Schulz K, Chalmers I, Hayes R, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412.
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163–171.
   PubMed Web of Science ®Google Scholar
• Owen R, Tincello D, Abrams K. Network meta-analysis: development of a three-level hierarchical modeling approach incorporating dose-related constraints. Value Health. 2015;18:116–126.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton A, Welton N, et al. Evidence synthesis for decision making 3: heterogeneity – subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013;33:618–640.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton N, Sutton A, et al. Evidence synthesis for decision making 1: introduction. Med Decis Making. 2013;33:597–606.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton N, Sutton A, et al. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33:641–656.
   PubMed Web of Science ®Google Scholar
• Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open. 2014;4:e004301.
   Web of Science ®Google Scholar
• Spiegelhalter DJ, Best NG, Carlin BP, et al. Bayesian measures of model complexity and fit. J Royal Statistical Soc B. 2002;64:583–639.
   Google Scholar
• Colombel J, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Feagan B, Lichtenstein G, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102–1111.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns RA, et al. Adalimumab rapidly induces clinical remission and response in patients with moderate to severe Crohn’s disease who had secondary failure to infliximab therapy: results of the GAIN study. Am J Gastroenterol. 2006;101:448.
   Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed: GEMINI III study. Gastroenterology. 2014;147:618–627.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337:1029–1036.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease. J Crohns Colitis. 2012;6:160–173.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease: GEMINI II study. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–1528.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349–1362.
   PubMed Web of Science ®Google Scholar
• Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clinic Proc. 2014;89:1621–1635.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology. 1999;5:1029–1034.
   Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. BMJ. 2007;56:1232–1239.
   Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. New England J Med. 2010;15:1383–1395.
   Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117:761–769.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin Gastroenterol Hepatol. 2008;6:1370–1377.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Macintosh DG, et al. Tu1138 efficacy of vedolizumab in Crohn’s disease by prior treatment failure in Gemini II, a randomized, placebo-controlled, double-blind, multicenter study. Gastroenterology. 2013;5:S-772.
   Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–818.
   PubMed Web of Science ®Google Scholar
• Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Therapeutics. 2004;201337–1346.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. New England J Med. 2007;357:228–238.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Reilly MC, Gerlier L, et al. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study. Aliment Pharmacol Therapeutics. 2010;31:1276–1285.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease. Int J Colorectal Disease. 2008;23:289–296.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Abreu MT, D’Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010;8:688–695.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab. 2011;33:5.
   Google Scholar
• Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled. Randomized Trial. 2011;9:8.
   Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. New England J Med. 2005;353:1912–1925.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2008;132:1672–1683.
   Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. New England J Med. 2003;348:24–32.
   PubMed Web of Science ®Google Scholar